← Back to Screener
Scilex Holding Company Common Stock (SCLX)
Price$7.99
Value ScoreB
Growth ScoreC
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)-68.96%
Price vs S&P 500 (4W)-20.85%
VGM Score57.55
Market Capitalization$75.57M
All Metrics
P/CF (Annual)19.80x
Book Value / Share (Quarterly)$0.07
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-7.34%
Cash Flow / Share (Quarterly)$-4.05
Price vs S&P 500 (YTD)-37.98%
Gross Margin (TTM)59.65%
Net Profit Margin (TTM)-1110.16%
EPS (TTM)$-35.63
10-Day Avg Trading Volume0.12M
EPS Excl Extra (TTM)$-35.63
Revenue Growth (5Y)5.13%
EPS (Annual)$-32.51
ROI (Annual)-64.46%
Gross Margin (Annual)64.97%
Net Profit Margin (5Y Avg)-380.55%
Cash / Share (Quarterly)$0.48
Revenue Growth QoQ (YoY)72.12%
ROA (Last FY)-98.29%
Revenue Growth TTM (YoY)-33.22%
EBITD / Share (TTM)$-35.70
Operating Margin (TTM)-1056.14%
Cash Flow / Share (Annual)$-1.84
P/B Ratio7.20x
P/B Ratio (Quarterly)78.88x
Net Income / Employee (Annual)$-10,551,000
EV / Revenue (TTM)4.85x
Net Interest Coverage (TTM)-17.27x
ROA (TTM)-147.67%
EPS Incl Extra (Annual)$-32.51
Current Ratio (Annual)0.08x
Quick Ratio (Quarterly)0.07x
3-Month Avg Trading Volume0.07M
52-Week Price Return57.52%
EV / Free Cash Flow (Annual)6.16x
Revenue / Employee (TTM)$995,900
Tangible BV / Share (Quarterly)$-2.27
P/S Ratio (Annual)2.50x
Asset Turnover (Annual)0.08x
52-Week High$34.27
Operating Margin (5Y Avg)-350.60%
EPS Excl Extra (Annual)$-32.51
CapEx CAGR (5Y)254.39%
26-Week Price Return-53.03%
Quick Ratio (Annual)0.05x
13-Week Price Return9.61%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)0.08x
Enterprise Value$164.17M
Revenue / Share Growth (5Y)75.07%
Asset Turnover (TTM)0.13x
Revenue / Employee (Annual)$889,800
Inventory Turnover (Annual)2.93x
Pretax Margin (Annual)-1236.33%
Cash / Share (Annual)$1.56
3-Month Return Std Dev113.23%
Gross Margin (5Y Avg)72.39%
Net Income / Employee (TTM)$-11,056,600
ROE (Last FY)-64.46%
Net Interest Coverage (Annual)-2.34x
EPS Basic Excl Extra (Annual)$-32.51
P/FCF (TTM)4.35x
Receivables Turnover (TTM)3.18x
EV / Free Cash Flow (TTM)27.02x
Total Debt / Equity (Quarterly)3.31x
EPS Incl Extra (TTM)$-35.63
Receivables Turnover (Annual)1.45x
P/S Ratio (TTM)2.23x
Pretax Margin (5Y Avg)-390.66%
Revenue / Share (Annual)$2.74
Tangible BV / Share (Annual)$-0.13
Forward P/E2.64x
Price vs S&P 500 (52W)29.32%
Year-to-Date Return-27.05%
5-Day Price Return45.66%
EPS Normalized (Annual)$-32.51
ROA (5Y Avg)-85.99%
Net Profit Margin (Annual)-1185.78%
Month-to-Date Return-15.40%
Cash Flow / Share (TTM)$-1.13
EBITD / Share (Annual)$-31.63
Operating Margin (Annual)-1168.01%
LT Debt / Equity (Annual)0.00x
P/CF (TTM)11.26x
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-35.63
P/B Ratio (Annual)15.56x
Inventory Turnover (TTM)3.62x
Pretax Margin (TTM)-1162.36%
Book Value / Share (Annual)$0.26
Price vs S&P 500 (13W)-0.14%
Beta1.70x
P/FCF (Annual)4.03x
Revenue / Share (TTM)$4.91
ROE (TTM)-130.91%
52-Week Low$4.20
vGradeB
gGradeC
mGradeB
vgmGradeC
Show chart for
Earnings Surprise History
Q4 25-2.21est. -0.48
Q1 26-4.76est. —
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
2.17
2.17
2.17
2.17
Industry Peers — Biological Products(178)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
SCLXScilex Holding Company Common Stock | B | C | B | $7.99 |
| AMGNAmgen Inc | C | C | C | $329.13 |
| GILDGilead Sciences Inc | C | B | C | $131.10 |
| ARGXargenx SE American Depositary Shares | D | A | C | $836.09 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $163.68 |
| BIIBBiogen Inc. Common Stock | B | D | B | $192.23 |
| BNTXBioNTech SE American Depositary Share | C | C | C | $91.70 |
| MRNAModerna, Inc. Common Stock | C | B | B | $46.06 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $161.00 |
| EXELExelixis Inc | C | B | B | $50.28 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | B | $298.10 |
About
Scilex Holding Co develops non-opioid pain management therapeutics for acute and chronic pain conditions. Commercial products include ZTlido (lidocaine topical system for postherpetic neuralgia) and Gloperba (colchicine oral solution for gout flare prevention). The clinical pipeline comprises SP-102 (corticosteroid gel for epidural injection), SP-103 (enhanced lidocaine formulation), and SP-104 (low-dose naltrexone capsule).